Problem: Unapproved stem-cell therapies are being marketed to people with long COVID

Unapproved stem-cell therapies marketed to people with long COVID Evgeniia Medvedeva/iStock CIDRAP

New research has identified 38 direct-to-consumer businesses marketing stem-cell treatments and exosome therapies for COVID-19 infections and, especially, long COVID, despite lacking approval by US Food and Drug Administration and other regulatory body in the United States. Descriptions of the businesses and an analysis of their marketing strategies are published in Stem Cell Reports.

...